Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

October 12, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

October 05, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Declares Fourth-Quarter 2023 Dividend

October 04, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

September 22, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 19, 2023

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

September 19, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts

September 18, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 12, 2023

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

September 11, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 05, 2023

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

August 30, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences

August 30, 2023

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV

August 24, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

August 21, 2023

From Pfizer Inc.

Via Business Wire

Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma

August 14, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Reports Second-Quarter 2023 Results

August 01, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

July 27, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility

July 21, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate

July 19, 2023

From Pfizer Inc.

Via Business Wire

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

June 28, 2023

From Pfizer Inc.

Via Business Wire

FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec

June 27, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus

June 26, 2023

From Pfizer Inc.

Via Business Wire

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

June 23, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Declares Third-Quarter 2023 Dividend

June 22, 2023

From Pfizer Inc.

Via Business Wire

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

June 20, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts

June 20, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

June 06, 2023

From Pfizer Inc.

Via Business Wire

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

June 01, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

May 31, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

May 30, 2023

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.